EUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION, DIABETES AND CHRONIC KIDNEY DISEASE, EUROASPIRE VI

The results of EUROASPIRE I, II, III, IV and V surveys demonstrated a high
prevalence of unhealthy lifestyles, modifiable risk factors and inadequate use
of drug therapies to achieve blood pressure and lipid goals in patients with
established CHD and people at high CVD risk, with wide variations in medical
practice between countries. Based on the EUROASPIRE methodology, an INTERASPIRE
survey is now being conducted in partnership with the World Heart Federation,
the European Society of Cardiology EuroObservational Research Programme and
other continental scientific societies encompassing all five WHO regions
outside Europe.
This sixth EUROASPIRE survey will investigate the cardiometabolic and renal
continuum in both secondary and primary cardiovascular disease prevention in
2023-2025 under the auspices of the European Society of Cardiology, Global
Registries And Surveys Programme (GRASP). As in the previous EUROASPIRE surveys
this survey will be focused on hospital patients with CHD, with and without
diabetes mellitus, and apparently healthy individuals in primary care at high
risk (hypertension, dyslipidaemia, diabetes) of developing CVD.

This sixth survey will give a unique European picture of preventive action by
cardiologists, other specialists and primary care physicians looking after
patients with CHD, individuals at high CVD risk and all those with
hypertension, dyslipidaemia (including familial hypercholesterolaemia),
diabetes and dysglycaemia and chronic kidney disease (CKD) and determine
whether the European guidelines on CVD prevention, hypertension, lipids,
diabetes and chronic kidney disease are being followed.

The objectives of EUROASPIRE VI survey of CVD prevention and diabetes are:
1. To determine in patients with established CHD (CHD = acute myocardial
infarction (AMI) and acute ischaemia (unstable angina) and patients following
revascularisation by a percutaneous coronary intervention (PCI) or coronary
artery by-pass graft surgery (CABG)) and in patients at high risk of developing
CVD risk, whether the 2021 European guidelines on CVD prevention are being
followed.
2. To compare diagnositic and therapeutic strategies in CHD and high-risk
patients for hypertension to determine whether the 2018 European guidelines on
hypertension are being followed.
3. To compare diagnostic and therapeutic strategies in CHD and high-risk
patients for glucose metabolism (impaired fasting glycaemia, impaired glucose
tolerance and diabetes) to determine whether the 2019 European guidelines on
diabetes, prediabetes and CVD are being followed.
4. To compare diagnostic and therapeutic strategies in CHD and high-risk
patients, including those with familial hypercholesterolaemia, for their lipid
(total cholesterol, HDL-cholesterol, triglycerides and Lp(a) management to
determine whether the 2019 lipid guidelines are being followed.
5. To compare diagnostic and therapeutic strategies in CHD and high-risk
patients for chronic kidney disease (either albuminuria and/or reduced kidney
function defined as an eGFR <60 ml/min/1.73 m2) to determine whether the CKD
guidelines (ADA/EASD, KDIGO) are being followed.
6. To determine whether organ-protective medications, that protect the heart
and the kidneys as recommended in the guidelines, are prescribed (and
up-titrated to the correct doses as appropriate) in every day clinical practice.
7. To determine whether the preventive strategies in patients with established
CHD in EUROASPIRE VI has improved by comparison with those hospital centres
which took part in previous EUROASPIRE surveys and whether the practice of
preventive cardiology in patients in primary care at high CVD risk in
EUROASPIRE VI has improved by comparison with those centres which took part in
EUROASPIRE III, IV and V.
8. To follow-up all coronary patients from EUROASPIRE VI one and five years
after the interview for hospitalisations, cardiovascular procedures,
cardiovascular events and cardiovascular and all cause mortality to determine
the impact of risk factors for CVD and their management and event- free
survival.
9. To identify strategies for improving preventive care based on the EUROASPIRE
survey results from hospital and general practice, and to make recommendations
to the European Association for Preventive Cardiology.

The ESC EUROASPIRE VI registry is an international multicentre, observational,
cross-sectional study of patients presenting to hospital and primary care
centres in countries whose National Cardiac Societies are ESC members.

The burden comprises a visit to the out-patients clinic, filling out
questionaires (< 5 minutes), a blood pressure measurement and a single blood
draw.